Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
54.59
-0.85 (-1.53%)
May 5, 2025, 4:00 PM EDT - Market closed
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2011 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2011 - 2019 |
| Total Vaccine |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Vaccine Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Pharmaceutical |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Pharmaceutical Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Dupixent |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Dupixent Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Neurology & Immunology |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Neurology & Immunology Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Oncology |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Oncology Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Blood Disorders |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Blood Disorders Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Core Assets |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Core Assets Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Non-Core Assets |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Non-Core Assets Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Industrial |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Industrial Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Care |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2011 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2011 - 2019 |
| Pharmaceutical Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vaccine Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vaccine Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Healthcare Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Healthcare Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare (Post-2022 Reporting) Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other (Post-2022 Reporting) Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other (Post-2022 Reporting) Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2011 - 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2011 - 2019 |
| United States |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|